Oncolytics Biotech Inc T.ONC

Transcript : Q4 2022 (ONCY) Conference Call March 3, 2023

[SundayMovies]

https://finance.yahoo.com/news/oncolytics-biotech-inc-nasdaq-oncy-144839193.html

[Noteable]

Upon review of this 'supposed' Yahoo transcript of the Q1'23 Investors Conference Call, and comparing this transcript to the original webinar call currently on record, I can say that the transcript is significantly "corrupted" with much information changed, watered-down, or completely left out. Whoever transcribed and posted this transcript on Yahoo appears to be trying to

[Noteable]

Andrew de Guttadauro also stated that Pfizer could be interested in the maturing Bracelet-1 data which would be revealed at ASCO (ORR, PFS and evolving OS) and thereafter.

[PeteZerria]

Hi Noteable,   A more or less complete transcript is available at seeking alpha. If you don’t have the App it can be found at https://seekingalpha.com/article/4600564-oncolytics-biotech-inc-oncy-q1-2023-earnings-call-transcript   Looks like it has all the discussions about Dr. Vile’s work with pela and CAR T, as well as the Q&A in its entirety.

[Noteable]

Thanks Pete - that's a accurate transcript https://seekingalpha.com/article/4600564-oncolytics-biotech-inc-oncy-q1-2023-earnings-call-transcript

[Noteable]

Andrew de Guttadauro also spoke of ONCY potentially receiving double digit royalities on aggregate CAR-T therapy + pelareorep sales. He stated that the CAR-T market in the US, EU, Japan and the ROW (ex China) is 135,000 new patients per year with a cost of US$400,000 per treatment. Instead of paying a double digit royalty on pelareorep, conventional thinking is that Big Pharma would prefer owing

[Noteable]

Correction: The CAR-T market in solid tumors is far greater than 135K patients per year but this is the approximate number of pancreatic patients per year.